Best Selling Rosuvastatin Lactone CAS NO (503610-43-3) in bulk quantity

Rosuvastatin lactone, with the Chemical Abstracts Service (CAS) number 503610-43-3, is an inactive lactone form of rosuvastatin, a member of the statin class of drugs used for lowering cholesterol levels in the blood. This lactone derivative is a precursor in the synthesis of the active form of rosuvastatin, which is known to inhibit HMG-CoA reductase, an enzyme involved in cholesterol biosynthesis.

1. Chemical Structure Rosuvastatin lactone is a lactone compound characterized by a cyclic ester ring. It is derived from rosuvastatin through lactonization, wherein the carboxylic acid group of rosuvastatin undergoes intramolecular esterification to form the lactone structure. The molecular formula of rosuvastatin lactone is C22H27FN3O6S.

2. Inactive Precursor In its lactone form, rosuvastatin is inactive and does not exhibit pharmacological activity. However, it serves as a prodrug that undergoes hydrolysis in vivo to yield the active form of rosuvastatin, which exerts its therapeutic effects by inhibiting HMG-CoA reductase in the liver.

3. Metabolic Activation Following oral administration, rosuvastatin lactone is absorbed into the systemic circulation and undergoes enzymatic hydrolysis mediated by esterases in the liver and other tissues. This hydrolysis converts rosuvastatin lactone back into the active acid form of rosuvastatin, which then inhibits HMG-CoA reductase and lowers cholesterol synthesis.

4. Pharmacokinetics The pharmacokinetics of rosuvastatin lactone are characterized by rapid absorption, distribution, and metabolism in the body. Upon hydrolysis to rosuvastatin, the active drug is extensively bound to plasma proteins and undergoes hepatic metabolism via cytochrome P450 enzymes before being excreted primarily in the feces.

5. Clinical Use Although rosuvastatin lactone itself is not administered therapeutically, it plays a crucial role as a precursor in the synthesis of rosuvastatin, which is widely used in the management of hypercholesterolemia and prevention of cardiovascular events. Rosuvastatin is available in oral formulations and is prescribed as part of lipid-lowering therapy in patients with dyslipidemia and cardiovascular risk factors.

6. Formulation Considerations Rosuvastatin lactone is typically used in the pharmaceutical industry as an intermediate in the synthesis of rosuvastatin calcium, the active pharmaceutical ingredient (API) in rosuvastatin-containing medications. Rosuvastatin calcium is formulated into tablets or capsules for oral administration, with various dosage strengths available to accommodate individual patient needs.

7. Safety and Tolerability Rosuvastatin lactone itself is generally considered safe and well-tolerated, as it is rapidly converted to the active form of rosuvastatin in the body. However, adverse effects associated with rosuvastatin therapy, such as myopathy, hepatotoxicity, and gastrointestinal disturbances, may occur with prolonged use and require monitoring.

8. Regulatory Approval Rosuvastatin calcium, the active form of rosuvastatin derived from rosuvastatin lactone, has received regulatory approval from health authorities worldwide for the treatment of hypercholesterolemia and prevention of cardiovascular events. It is marketed under various brand names and is available as a generic medication in many countries.

9. Future Perspectives Research continues to explore the clinical efficacy and safety of rosuvastatin and other statins in the management of cardiovascular diseases and associated risk factors. Additionally, efforts to optimize drug formulations, dosing regimens, and therapeutic strategies aim to improve patient outcomes and reduce the global burden of cardiovascular morbidity and mortality.

10. Conclusion Rosuvastatin lactone serves as an essential precursor in the synthesis of rosuvastatin, a widely prescribed medication for lowering cholesterol levels and reducing cardiovascular risk. While inactive itself, rosuvastatin lactone plays a crucial role in the pharmacological activation of rosuvastatin in the body, highlighting its significance in cardiovascular medicine and lipid-lowering therapy.